{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T21:56:13Z","timestamp":1783634173885,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2008,8,1]],"date-time":"2008-08-01T00:00:00Z","timestamp":1217548800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Antibiot"],"published-print":{"date-parts":[[2008,8]]},"DOI":"10.1038\/ja.2008.65","type":"journal-article","created":{"date-parts":[[2009,1,16]],"date-time":"2009-01-16T15:00:17Z","timestamp":1232118017000},"page":"489-495","source":"Crossref","is-referenced-by-count":8,"title":["Rifalazil Retains Activity Against Rifampin-resistant Mutants of Chlamydia pneumoniae"],"prefix":"10.1038","volume":"61","author":[{"given":"David M","family":"Rothstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J","family":"Suchland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minsheng","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher K","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter E","family":"Stamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BFja200865_CR1","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1128\/AAC.39.7.1489","volume":"39","author":"K Fujii","year":"1995","unstructured":"Fujii K, Saito H, Tomioka H, Mae T, Hosoe K . Mechanism of action of antimycobacterial activity of the new benzoxazinorifamycin KRM-1648. Antimicrob Agents Chemother 39: 1489\u20131492 ( 1995)","journal-title":"Antimicrob Agents Chemother"},{"key":"BFja200865_CR2","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1128\/AAC.45.7.1972-1976.2001","volume":"45","author":"R Dietze","year":"2001","unstructured":"Dietze R . Teixeira L, Rocha LM, Palaci M, Johnson JL, Wells C, Rose L, Eisenach K, Ellner JJ . Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis. Antimicrob Agents Chemother 45: 1972\u20131976 ( 2001)","journal-title":"Antimicrob Agents Chemother"},{"key":"BFja200865_CR3","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1517\/13543784.12.2.255","volume":"12","author":"DM Rothstein","year":"2003","unstructured":"Rothstein DM, Hartman AD, Cynamon MH, Eisenstein BI . Development potential of rifalazil. Expert Opin Investig Drugs 12: 255\u2013271 ( 2003).","journal-title":"Expert Opin Investig Drugs"},{"key":"BFja200865_CR4","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1128\/AAC.47.3.1135-1136.2003","volume":"47","author":"PM Roblin","year":"2003","unstructured":"Roblin PM, Reznik T, Kutlin A, Hammerschlag MR . In vitro activities of rifamycin derivatives ABI-1648 (rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae. Antimicrob Agents Chemother 47: 1135\u20131136 ( 2003)","journal-title":"Antimicrob Agents Chemother"},{"key":"BFja200865_CR5","unstructured":"Stamm WE, Geisler WM, Suchland RJ . Assessment of antimicrobial resistance in Chlamydia trachomatis strains associated with treatment failure or same strain recurrence, pp. 353\u2013360. In Chlamydial infections: Proceedings of the 10th International Symposium on Human Chlamydial Infections. Basim Yeri: GRAFMAT Basim ve Reklam Sanayi Tic. Ltd. Sti., Antalya, Turkey ( 2002)"},{"key":"BFja200865_CR6","first-page":"317","volume-title":"Expanding indications for the new macrolides, azalides, and streptogramins","author":"C-C Kuo","year":"1997","unstructured":"Kuo C-C, Grayston JT, Hidaka T, Rose LM . A comparison of the in vitro sensitivity of Chlamydia pneumoniae to macrolides and a new benzoxazinorifamycin, KRM-1648. In Expanding indications for the new macrolides, azalides, and streptogramins. Infectious disease and therapy series, Vol. 21, Ed., Zinner SH, et al., pp. 317\u2013321, Marcel Dekker, New York, N.Y. ( 1997)"},{"key":"BFja200865_CR7","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1128\/AAC.01567-07","volume":"52","author":"LA Campbell","year":"2008","unstructured":"Campbell LA, Kuo CC, Suchland RJ, Rothstein DM . Efficacy of benzoxazinorifamycins in a mouse model of Chlamydia pneumoniae lung infection. Antimicrob Agents Chemother 52: 1855\u20131858 ( 2008)","journal-title":"Antimicrob Agents Chemother"},{"key":"BFja200865_CR8","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/S0140-6736(98)12387-5","volume":"354","author":"J Schachter","year":"1999","unstructured":"Schachter J, West SK, Mabey D, Dawson CR, Bobo L, Bailey R, Vitale S, Quinn TC, Sheta A, Sallam S, Mkocha H, Mabey D, Faal H . Azithromycin in control of trachoma. Lancet 354: 630\u2013635 ( 1999)","journal-title":"Lancet"},{"key":"BFja200865_CR9","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1146\/annurev.me.43.020192.001533","volume":"43","author":"JT Grayston","year":"1992","unstructured":"Grayston JT . Chlamydia pneumoniae, strain TWAR pneumonia. Annu Rev Med 43: 317\u2013323 ( 1992)","journal-title":"Annu Rev Med"},{"key":"BFja200865_CR10","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1128\/mr.58.4.686-699.1994","volume":"58","author":"WL Beatty","year":"1994","unstructured":"Beatty WL, Morrison RP, Byrne GI . Persistent chlamydiae: from cell culture to a paradigm for chlamydial pathogenesis. Microbiol Rev 58: 686\u2013699 ( 1994)","journal-title":"Microbiol Rev"},{"key":"BFja200865_CR11","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1111\/j.1365-2958.2006.05465.x","volume":"62","author":"SP Ouellette","year":"2006","unstructured":"Ouellette SP, Hatch TP, AbdelRahman YM, Rose LA, Belland RJ, Byrne GI . Global transcriptional upregulation in the absence of increased translation in Chlamydia during IFNgamma-mediated host cell tryptophan starvation. Mol Microbiol 62: 1387\u20131401 ( 2006)","journal-title":"Mol Microbiol"},{"key":"BFja200865_CR12","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1128\/AAC.40.12.2749","volume":"40","author":"K Hosoe","year":"1996","unstructured":"Hosoe K, Mae T, Konishi E, Fujii K, Yamashita K, Yamane T, Hidaka T, Ohashi T . Pharmacokinetics of KRM-1648, a new benzoxazinorifamycin, in rats and dogs. Antimicrob Agents Chemother 40: 2749\u20132755 ( 1996)","journal-title":"Antimicrob Agents Chemother"},{"key":"BFja200865_CR13","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1517\/13543784.15.6.603","volume":"15","author":"DM Rothstein","year":"2006","unstructured":"Rothstein DM, Shalish C, Murphy CK, Sternlicht A, Campbell LA . Development potential of rifalazil and other benzoxazinorifamycins. Expert Opin Investig Drugs 15: 603\u2013623 ( 2006)","journal-title":"Expert Opin Investig Drugs"},{"key":"BFja200865_CR14","doi-asserted-by":"crossref","unstructured":"Stamm WE, Batteiger BE, McCormack WM, Totten PA, Sternlicht A, Kivel NM . For the Rifalazil Study Group. A Randomized, Double-Blind Study Comparing Single-Dose Rifalazil With Single-Dose Azithromycin for the Empirical Treatment of Nongonococcal Urethritis in Men. Sex Transm Dis. Feb 8; [Epub ahead of print] ( 2007)","DOI":"10.1097\/01.olq.0000253348.44308.8c"},{"key":"BFja200865_CR15","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/ardp.200700080","volume":"340","author":"DM Rothstein","year":"2007","unstructured":"Rothstein DM, Van Duzer J, Sternlicht A, Gilman SC . Rifalazil and other benzoxazinorifamycins in the treatment of Chlamydia-based persistent infections. Arch Pharm (Weinheim) 340: 517\u2013529 ( 2007)","journal-title":"Arch Pharm (Weinheim)"},{"key":"BFja200865_CR16","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1128\/AAC.40.11.2655","volume":"40","author":"SL Moghazeh","year":"1996","unstructured":"Moghazeh SL, Pan X, Arain T, Stover CK, Musser JM, Kreiswirth BN . Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Antimicrob Agents Chemother 40: 2655\u20132657 ( 1996)","journal-title":"Antimicrob Agents Chemother"},{"key":"BFja200865_CR17","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1128\/AAC.42.7.1853","volume":"42","author":"DL Williams","year":"1998","unstructured":"Williams DL, Spring L, Collins L, Miller LP, Heifets LB, Gangadharam PR, Gillis TP . Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 42: 1853\u20131857 ( 1998)","journal-title":"Antimicrob Agents Chemother"},{"key":"BFja200865_CR18","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1093\/jac\/42.5.621","volume":"42","author":"B Yang","year":"1998","unstructured":"Yang B, Koga H, Ohno H, Ogawa K, Fukuda M, Hirakata Y, Maesaki S, Tomono K, Tashiro T, Kohno S . Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis. J Antimicrob Chemother 42: 621\u2013628 ( 1998)","journal-title":"J Antimicrob Chemother"},{"key":"BFja200865_CR19","first-page":"166","volume":"6","author":"YK Park","year":"2002","unstructured":"Park YK, Kim BJ, Ryu S, Kook YH, Choe YK, Bai GH, Kim SJ . Cross-resistance between rifampicin and KRM-1648 is associated with specific rpoB alleles in Mycobacterium tuberculosis. Int J Tuberc Lung Dis 6: 166\u2013170 ( 2002)","journal-title":"Int J Tuberc Lung Dis"},{"key":"BFja200865_CR20","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1128\/AAC.43.11.2813","volume":"43","author":"TA Wichelhaus","year":"1999","unstructured":"Wichelhaus TA, Schafer V, Brade V, Boddinghaus B . Molecular characterization of rpoB mutations conferring cross-resistance to rifamycins on methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 43: 2813\u20132816 ( 1999)","journal-title":"Antimicrob Agents Chemother"},{"key":"BFja200865_CR21","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1093\/jac\/47.2.153","volume":"47","author":"TA Wichelhaus","year":"2001","unstructured":"Wichelhaus TA, Schafer V, Brade V, Boddinghaus B . Differential effect of rpoB mutations on antibacterial activities of rifampicin and KRM-1648 against Staphylococcus aureus. J Antimicrob Chemother 47: 153\u2013156 ( 2001)","journal-title":"J Antimicrob Chemother"},{"key":"BFja200865_CR22","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1128\/AAC.50.3.827-834.2006","volume":"50","author":"CK Murphy","year":"2006","unstructured":"Murphy CK, Mullin S, Osburne MS, Van Duzer J, Siedlecki J, Yu X, Kerstein K, Cynamon M, Rothstein DM . In vitro activity of novel rifamycins against rifamycin-resistant Staphylococcus aureus. Antimicro Agents Chemother 50: 827\u2013834 ( 2006)","journal-title":"Antimicro Agents Chemother"},{"key":"BFja200865_CR23","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1128\/AAC.50.5.1908-1909.2006","volume":"50","author":"S Mullin","year":"2006","unstructured":"Mullin S, Rothstein DM, Murphy CK . Activity of novel benzoxazinorifamycins against rifamycin-resistant Streptococcus pyogenes. Antimicrob Agents Chemother 50: 1908\u20131911 ( 2006)","journal-title":"Antimicrob Agents Chemother"},{"key":"BFja200865_CR24","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1128\/AAC.49.3.1120-1126.2005","volume":"49","author":"RJ Suchland","year":"2005","unstructured":"Suchland RJ, Bourillon A, Denamur E, Stamm WE, Rothstein DM . Rifampin-resistant RNA polymerase mutants of Chlamydia trachomatis remain susceptible to the ansamycin rifalazil. Antimicrob Agents Chemother 49: 1120\u20131126 ( 2005)","journal-title":"Antimicrob Agents Chemother"},{"key":"BFja200865_CR25","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1128\/AAC.49.3.903-907.2005","volume":"49","author":"A Kutlin","year":"2005","unstructured":"Kutlin A, Kohlhoff S, Roblin P, Hammerschlag MR, Riska P . Emergence of resistance to rifampin and rifalazil in Chlamydophila pneumoniae and Chlamydia trachomatis. Antimicrob Agents Chemother. 49: 903\u2013907 ( 2005)","journal-title":"Antimicrob Agents Chemother"},{"key":"BFja200865_CR26","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1128\/AAC.47.2.636-642.2003","volume":"47","author":"RJ Suchland","year":"2003","unstructured":"Suchland RJ, Geisler WM, Stamm WE . Methodologies and cell lines used for antimicrobial susceptibility testing of Chlamydia spp. Antimicrob Agents Chemother 47: 636\u2013642 ( 2003)","journal-title":"Antimicrob Agents Chemother"},{"key":"BFja200865_CR27","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1128\/AAC.50.2.439-444.2006","volume":"50","author":"RJ Suchland","year":"2006","unstructured":"Suchland RJ, Brown K, Rothstein DM, Stamm WE . Rifalazil pretreatment of mammalian cell cultures prevents subsequent Chlamydia infection. Antimicrob Agents Chemother 50: 439\u2013444 ( 2006)","journal-title":"Antimicrob Agents Chemother"},{"key":"BFja200865_CR28","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S0092-8674(01)00286-0","volume":"104","author":"EA Campbell","year":"2001","unstructured":"Campbell EA, Korzheva N, Mustaev A, Murakami K, Nair S, Goldfarb A, Darst SA . Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell 104: 901\u2013912 ( 2001)","journal-title":"Cell"},{"key":"BFja200865_CR29","doi-asserted-by":"publisher","first-page":"3974","DOI":"10.1128\/AAC.49.9.3974-3976.2005","volume":"49","author":"M Xia","year":"2005","unstructured":"Xia M, Suchland RJ, Carswell JA, Van Duzer J, Buxton DK, Brown K, Rothstein DM, Stamm WE . Activities of rifamycin derivatives against wild-type and rpoB mutants of Chlamydia trachomatis. Antimicrob Agents Chemother 49: 3974\u20133976 ( 2005)","journal-title":"Antimicrob Agents Chemother"}],"container-title":["The Journal of Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ja200865.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ja200865","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ja200865.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T17:13:43Z","timestamp":1684430023000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ja200865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["BFja200865"],"URL":"https:\/\/doi.org\/10.1038\/ja.2008.65","relation":{},"ISSN":["0021-8820","1881-1469"],"issn-type":[{"value":"0021-8820","type":"print"},{"value":"1881-1469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8]]}}}